SG11201408808WA - Method and system for treatment of biological tissue - Google Patents
Method and system for treatment of biological tissueInfo
- Publication number
- SG11201408808WA SG11201408808WA SG11201408808WA SG11201408808WA SG11201408808WA SG 11201408808W A SG11201408808W A SG 11201408808WA SG 11201408808W A SG11201408808W A SG 11201408808WA SG 11201408808W A SG11201408808W A SG 11201408808WA SG 11201408808W A SG11201408808W A SG 11201408808WA
- Authority
- SG
- Singapore
- Prior art keywords
- lllll
- international
- llll
- biological tissue
- iii
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3633—Extracellular matrix [ECM]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
- A61L27/367—Muscle tissue, e.g. sphincter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
- A61L27/3873—Muscle tissue, e.g. sphincter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/20—Surgical instruments, devices or methods, e.g. tourniquets for vaccinating or cleaning the skin previous to the vaccination
- A61B17/205—Vaccinating by means of needles or other puncturing devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/00234—Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
- A61B2017/00238—Type of minimally invasive operation
- A61B2017/00243—Type of minimally invasive operation cardiac
- A61B2017/00247—Making holes in the wall of the heart, e.g. laser Myocardial revascularization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/20—Materials or treatment for tissue regeneration for reconstruction of the heart, e.g. heart valves
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 27 March 2014 (27.03.2014) WIPOIPCT (10) International Publication Number WO 2014/046744 A1 (51) International Patent Classification: A61K 35/38 (2006.01) A61K 31/727 (2006.01) A61K35/00 (2006.01) (21) International Application Number: PCT/US2013/043087 (22) International Filing Date: 29 May 2013 (29.05.2013) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 13/573,569 24 September 2012 (24.09.2012) US (71) Applicant: CORMATRIX CARDIOVASCULAR, INC. [US/US]; 1100 Old Ellis Road, Roswell, GA 30076 (US). (72) Inventor: MATHENY, Robert, G.; 4370 River Bottom Road, Norcross, GA 30092 (US). (74) Agent: FRANCIS, Ralph, C ; Francis Law Group, 512 Westline Drive, Suite 301, Alameda, CA 94501 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). [Continued on next page] (54) Title: METHOD AND SYSTEM FOR TREATMENT OF BIOLOGICAL TISSUE (57) Abstract: A composition for reconstmction, replacement or repair of damaged or diseased biological tissue comprising an ex tracellular matrix (ECM) composition that includes an ECM scaffold component derived from a mammalian source and at least one additional bioactive component selected from the group consisting of a statin and chitin derivative. a FIG 2 WO 2014/046744 A11 lllll llllllll II llllll III III lllll llll lllll lllll lllll III III lllll lllll llll lllllll llll llll llll Published: — with international search report (Art. 21(3))
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/573,569 US9072816B2 (en) | 2006-01-18 | 2012-09-24 | Composition for modulating inflammation of cardiovascular tissue |
PCT/US2013/043087 WO2014046744A1 (en) | 2012-09-24 | 2013-05-29 | Method and system for treatment of biological tissue |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201408808WA true SG11201408808WA (en) | 2015-01-29 |
Family
ID=50342519
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201408808WA SG11201408808WA (en) | 2012-09-24 | 2013-05-29 | Method and system for treatment of biological tissue |
SG11201501649TA SG11201501649TA (en) | 2012-09-24 | 2013-06-14 | Method and system for treatment of biological tissue |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201501649TA SG11201501649TA (en) | 2012-09-24 | 2013-06-14 | Method and system for treatment of biological tissue |
Country Status (11)
Country | Link |
---|---|
US (3) | US9072816B2 (en) |
EP (3) | EP2887948A4 (en) |
JP (3) | JP2015532922A (en) |
CN (1) | CN104703614A (en) |
AU (3) | AU2013318632A1 (en) |
BR (2) | BR112014031796A2 (en) |
CA (3) | CA2875302A1 (en) |
IL (2) | IL236021A0 (en) |
IN (1) | IN2015DN01780A (en) |
SG (2) | SG11201408808WA (en) |
WO (3) | WO2014046744A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9283302B2 (en) | 2011-12-16 | 2016-03-15 | Cormatrix Cardiovascular, Inc. | Extracellular matrix encasement structures and methods |
US20080279833A1 (en) | 2007-05-10 | 2008-11-13 | Matheny Robert G | Laminate sheet articles for tissue regeneration |
AU2010216095B2 (en) * | 2009-02-18 | 2015-10-08 | Cormatrix Cardiovascular, Inc. | Compositions and methods for preventing cardiac arrhythmia |
US20160143720A1 (en) * | 2014-11-26 | 2016-05-26 | Cormatrix Cardiovascular, Inc. | Mesh Fiber Members and Methods for Forming and Using Same for Treating Damaged Biological Tissue |
US20160143738A1 (en) * | 2014-11-26 | 2016-05-26 | Cormatrix Cardiovascular, Inc. | Biological Constructs for Treating Damaged Organs and Tissue |
WO2016093863A1 (en) * | 2014-12-10 | 2016-06-16 | Cormatrix Cardiovascular, Inc. | Method and system for treatment of damaged biological tissue |
KR20180015187A (en) * | 2015-06-03 | 2018-02-12 | 위스콘신 얼럼나이 리서어치 화운데이션 | Cardiomyocyte-injectable formulations thereof for the treatment of derived extracellular matrix and ischemic diseases or disorders |
WO2017189986A1 (en) * | 2016-04-28 | 2017-11-02 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Compositions comprising extracellular matrix of primitive animal species and related methods |
EP3380045B1 (en) | 2016-07-11 | 2024-02-21 | Cormatrix Cardiovascular, Inc. | Prosthetic tissue valves |
KR101710615B1 (en) * | 2016-09-07 | 2017-02-27 | 주식회사 파마리서치프로덕트 | Dermal matrix for transplantation having improved survival rate and method for preparing thereof |
WO2019241910A1 (en) * | 2018-06-19 | 2019-12-26 | 中国医学科学院阜外医院 | Method for preparing mesenchymal stem cell-derived exosomes on basis of drug pretreatment |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5275826A (en) * | 1992-11-13 | 1994-01-04 | Purdue Research Foundation | Fluidized intestinal submucosa and its use as an injectable tissue graft |
US6485723B1 (en) * | 1995-02-10 | 2002-11-26 | Purdue Research Foundation | Enhanced submucosal tissue graft constructs |
AU722065B2 (en) * | 1996-11-05 | 2000-07-20 | Purdue Research Foundation | Myocardial graft constructs |
ES2263185T3 (en) * | 1996-12-10 | 2006-12-01 | Purdue Research Foundation | BIOMATERIAL DERIVED FROM VERPABRADO HEPATIC FABRIC. |
EP0944647B1 (en) * | 1996-12-10 | 2008-11-12 | Purdue Research Foundation | Submucosa extracts |
IL139708A0 (en) * | 2000-11-15 | 2002-02-10 | Amiel Gilad | Process of decellularizing biological matrices and acellular biological matrices useful in tissue engineering |
JP2005515802A (en) * | 2001-07-16 | 2005-06-02 | デピュイ・プロダクツ・インコーポレイテッド | Hybrid / Synthetic Porous Extracellular Matrix Support Skeleton |
US20040078090A1 (en) * | 2002-10-18 | 2004-04-22 | Francois Binette | Biocompatible scaffolds with tissue fragments |
US20040175366A1 (en) * | 2003-03-07 | 2004-09-09 | Acell, Inc. | Scaffold for cell growth and differentiation |
US20060178424A1 (en) * | 2003-06-18 | 2006-08-10 | Stanley Nattel | Preventing atrial fibrillation (af) with the use of stain drugs |
EP1644011A1 (en) * | 2003-06-25 | 2006-04-12 | Stephen F. Badylak | Conditioned matrix compositions for tissue restoration |
FI20045223A (en) * | 2004-06-15 | 2005-12-16 | Bioretec Oy | A multifunctional biodegradable composite and a surgical implant comprising said composite |
US20050013870A1 (en) * | 2003-07-17 | 2005-01-20 | Toby Freyman | Decellularized extracellular matrix of conditioned body tissues and uses thereof |
GB2423934B (en) * | 2003-09-04 | 2007-11-28 | Cook Biotech Inc | Extracellular matrix composite materials, and manufacture and use thereof |
US8454678B2 (en) * | 2005-03-19 | 2013-06-04 | Cook Biotech Incorporated | Prosthetic implants including ECM composite material |
US20060293760A1 (en) * | 2005-06-24 | 2006-12-28 | Dedeyne Patrick G | Soft tissue implants with improved interfaces |
US8568761B2 (en) * | 2005-07-15 | 2013-10-29 | Cormatrix Cardiovascular, Inc. | Compositions for regenerating defective or absent myocardium |
US9532943B2 (en) * | 2010-12-20 | 2017-01-03 | Cormatrix Cardiovascular, Inc. | Drug eluting patch for the treatment of localized tissue disease or defect |
WO2008021127A2 (en) * | 2006-08-08 | 2008-02-21 | Howmedica Osteonics Corp. | Expandable cartilage implant |
US8361503B2 (en) * | 2007-03-02 | 2013-01-29 | University of Pittsburgh—of the Commonwealth System of Higher Education | Extracellular matrix-derived gels and related methods |
EP2237770A4 (en) * | 2007-12-26 | 2011-11-09 | Gel Del Technologies Inc | Biocompatible protein particles, particle devices and methods thereof |
WO2009086499A2 (en) | 2007-12-28 | 2009-07-09 | Cook Biotech Incorporated | Medical composition including an extracellular matrix particulate |
JP2010059235A (en) * | 2008-09-01 | 2010-03-18 | Fujifilm Corp | Ultraviolet absorbent composition |
CA2741770C (en) * | 2008-09-30 | 2018-01-23 | The Regents Of The University Of California | Compositions and methods for tissue repair with extracellular matrices |
AU2010216095B2 (en) | 2009-02-18 | 2015-10-08 | Cormatrix Cardiovascular, Inc. | Compositions and methods for preventing cardiac arrhythmia |
-
2012
- 2012-09-24 US US13/573,569 patent/US9072816B2/en active Active
-
2013
- 2013-05-01 US US13/874,942 patent/US20140087000A1/en not_active Abandoned
- 2013-05-29 AU AU2013318632A patent/AU2013318632A1/en not_active Abandoned
- 2013-05-29 CA CA2875302A patent/CA2875302A1/en not_active Abandoned
- 2013-05-29 CN CN201380049450.3A patent/CN104703614A/en active Pending
- 2013-05-29 WO PCT/US2013/043087 patent/WO2014046744A1/en active Application Filing
- 2013-05-29 SG SG11201408808WA patent/SG11201408808WA/en unknown
- 2013-05-29 JP JP2015533045A patent/JP2015532922A/en active Pending
- 2013-05-29 EP EP13838953.1A patent/EP2887948A4/en not_active Withdrawn
- 2013-05-29 BR BR112014031796A patent/BR112014031796A2/en not_active IP Right Cessation
- 2013-06-14 WO PCT/US2013/046041 patent/WO2014046753A2/en active Application Filing
- 2013-06-14 AU AU2013318552A patent/AU2013318552A1/en not_active Abandoned
- 2013-06-14 JP JP2015533049A patent/JP2015531664A/en active Pending
- 2013-06-14 SG SG11201501649TA patent/SG11201501649TA/en unknown
- 2013-06-14 EP EP13839300.4A patent/EP2897623A4/en not_active Withdrawn
- 2013-06-14 BR BR112015006512A patent/BR112015006512A2/en not_active IP Right Cessation
- 2013-06-14 CA CA2883885A patent/CA2883885A1/en not_active Abandoned
- 2013-06-15 AU AU2013318551A patent/AU2013318551B2/en not_active Ceased
- 2013-06-15 CA CA2884959A patent/CA2884959C/en not_active Expired - Fee Related
- 2013-06-15 WO PCT/US2013/046039 patent/WO2014046752A1/en active Application Filing
- 2013-06-15 JP JP2015533048A patent/JP2015532923A/en active Pending
- 2013-06-15 EP EP13839811.0A patent/EP2897624A4/en not_active Withdrawn
-
2014
- 2014-12-01 IL IL236021A patent/IL236021A0/en unknown
- 2014-12-17 US US14/573,017 patent/US20150099007A1/en not_active Abandoned
-
2015
- 2015-03-04 IN IN1780DEN2015 patent/IN2015DN01780A/en unknown
- 2015-03-04 IL IL237568A patent/IL237568A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2887948A1 (en) | 2015-07-01 |
EP2897623A4 (en) | 2016-07-06 |
BR112015006512A2 (en) | 2017-08-08 |
US9072816B2 (en) | 2015-07-07 |
EP2897624A4 (en) | 2016-05-18 |
WO2014046752A1 (en) | 2014-03-27 |
US20130058904A1 (en) | 2013-03-07 |
IL237568A0 (en) | 2015-04-30 |
IL236021A0 (en) | 2015-01-29 |
CA2884959A1 (en) | 2014-03-27 |
JP2015532922A (en) | 2015-11-16 |
CA2884959C (en) | 2021-08-17 |
IN2015DN01780A (en) | 2015-05-29 |
EP2897624A1 (en) | 2015-07-29 |
SG11201501649TA (en) | 2015-04-29 |
US20140087000A1 (en) | 2014-03-27 |
CA2883885A1 (en) | 2014-03-27 |
WO2014046744A1 (en) | 2014-03-27 |
WO2014046753A3 (en) | 2015-06-25 |
CN104703614A (en) | 2015-06-10 |
WO2014046753A2 (en) | 2014-03-27 |
AU2013318551B2 (en) | 2018-06-14 |
AU2013318552A1 (en) | 2015-03-19 |
EP2897623A2 (en) | 2015-07-29 |
CA2875302A1 (en) | 2014-03-27 |
JP2015532923A (en) | 2015-11-16 |
JP2015531664A (en) | 2015-11-05 |
EP2887948A4 (en) | 2016-04-13 |
AU2013318551A1 (en) | 2015-04-02 |
BR112014031796A2 (en) | 2017-06-27 |
AU2013318632A1 (en) | 2015-01-15 |
US20150099007A1 (en) | 2015-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201408808WA (en) | Method and system for treatment of biological tissue | |
SG11201811225RA (en) | Ar+ breast cancer treatment methods | |
SG11201408261UA (en) | Syringe | |
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201906431UA (en) | Method for the treatment of thromboembolism | |
SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
SG11201804134YA (en) | Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment | |
SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
SG11201407417VA (en) | Encoding and reconstruction of residual data based on support information | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
SG11201407851RA (en) | Synthesis of pyrrolo [2, 3 - b] pyridines | |
SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
SG11201407546QA (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
SG11201406903SA (en) | Cell culture compositions and methods for polypeptide production | |
SG11201900405XA (en) | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia | |
SG11201408037SA (en) | Humanized anti-trka antibodies with amino acid substitutions | |
SG11201908472VA (en) | Compositions and methods for activating nk cells | |
SG11201810429UA (en) | Anti-cd19 antibody formulations | |
SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier |